Skip to main content

Volume 6 Supplement 3

Metabolism, diet and disease

  • Oral presentation
  • Open access
  • Published:

Beyond insulin: rethinking cellular metabolism

The latest cancer therapeutics are almost all inhibitors of oncogenes or their downstream mediators. With the exception of imatinib, most such drugs have been disappointing in the clinic. In contrast, existing successful cancer drugs have a therapeutic index because they render the consequences of oncogene activation selectively toxic to the cancer cell. A renewed focus on this type of approach appears warranted and should be considered.

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Thompson, C.B. Beyond insulin: rethinking cellular metabolism. BMC Proc 6 (Suppl 3), O25 (2012).

Download citation

  • Published:

  • DOI: